 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
2 March 2004 | Volume 140 Issue 5 | Pages 330-337
Background: Odds ratios for venous thromboembolism (deep venous thrombosis and pulmonary embolism) derived from case–control studies range from 3 to 16 for heterozygotes compared with noncarriers and up to 79 for homozygotes compared with noncarriers.
Objective: To estimate risks for venous thromboembolism in the adult Danish population according to factor V Leiden genotype.
Design: Cohort study with 23 years of follow-up.
Setting: Adult Danish population.
Participants: 9253 randomly selected individuals.
Measurements: Hospitalization and death from venous thromboembolism, factor V Leiden genotype, and additional thromboembolic risk factors.
Results: Adjusted hazard ratios in heterozygotes and homozygotes compared with noncarriers were 2.7 (95% CI, 1.8 to 3.8) and 18 (CI, 4.1 to 41) for venous thromboembolism overall, 2.4 (CI, 1.3 to 3.8) and 22 (CI, 0 to 60) for deep venous thrombosis, and 3.0 (CI, 1.7 to 4.9) and 11 (CI, 0 to 33) for pulmonary embolism. The lowest absolute 10-year risks for venous thromboembolism in factor V Leiden heterozygotes and homozygotes—0.7% (CI, 0.5% to 1.0%) and 3% (CI, 1% to 8%)—were found in nonsmokers younger than 40 years of age with a body mass index below 25 kg/m2; the corresponding highest risks—10% (CI, 7% to 14%) and 51% (CI, 13% to 100%)—were found in smokers older than 60 years of age with a body mass index above 30 kg/m2.
Conclusions: Hazard ratios for venous thromboembolism in factor V Leiden heterozygotes and homozygotes compared with noncarriers in the adult Danish population were approximately 3 and 18, respectively. The simultaneous presence of smoking, obesity, and old age resulted in absolute 10-year thromboembolic risks of 10% in heterozygotes and 51% in homozygotes.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From Herlev University Hospital, Herlev, Denmark; Rigshospitalet, Copenhagen University Hospital, University of Copenhagen, and The Copenhagen City Heart Study, Bispebjerg University Hospital, Copenhagen, Denmark.
Acknowledgments: The authors thank Hanne Damm for technical assistance and the participants of the Copenhagen City Heart Study for their willingness to participate.
Grant Support: By grants from the Danish Heart Foundation, the Danish Medical Research Council, Chief Physician Johan Boserup and Lise Boserup's Fund, Lykfeldt's Fund, Dagmar Marshall's Fund, Wedelborg's Fund, Lily Benthine Lund's Fund, the Beckett Fund, and P. Carl Petersen's Fund.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark; e-mail, brno{at}herlevhosp.kbhamt.dk.
Current Author Addresses: Drs. Juul and Nordestgaard: Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
Dr. Tybjærg-Hansen: Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 3, DK-2100 Copenhagen, Denmark.
Dr. Schnohr: The Copenhagen City Heart Study, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark.
Author Contributions: Conception and design: K. Juul, A. Tybjærg-Hansen, P. Schnohr, B.G. Nordestgaard.
Analysis and interpretation of the data: K. Juul, A. Tybjærg-Hansen, B.G. Nordestgaard.
Drafting of the article: K. Juul.
Critical revision of the article for important intellectual content: K. Juul, A. Tybjærg-Hansen, B.G. Nordestgaard.
Final approval of the article: K. Juul, A. Tybjærg-Hansen, B.G. Nordestgaard.
Statistical expertise: K. Juul, A. Tybjærg-Hansen, B.G. Nordestgaard.
Obtaining of funding: K. Juul, A. Tybjærg-Hansen, B.G. Nordestgaard.
Collection and assembly of data: K. Juul, A. Tybjærg-Hansen, P. Schnohr, B.G. Nordestgaard. ARTICLE
Factor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. J. Freiberg, A. Tybjaerg-Hansen, H. Sillesen, G. B. Jensen, and B. G. Nordestgaard Promotor Polymorphisms in Leukotriene C4 Synthase and Risk of Ischemic Cerebrovascular Disease Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 990 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study Circulation, January 15, 2008; 117(2): 176 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Har-Noy and E. Meltzer Upper-extremity deep-vein thrombosis in an elderly man Can. Med. Assoc. J., April 10, 2007; 176(8): 1078 - 1079. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kruse, A. M. Mitchell, C. A. Camargo Jr, J. Hernandez, and J. A. Kline Frequency of Thrombophilia-Related Genetic Variations in Patients with Idiopathic Pulmonary Embolism in an Urban Emergency Department Clin. Chem., June 1, 2006; 52(6): 1026 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Juul, A. Tybjaerg-Hansen, J. Mortensen, P. Lange, J. Vestbo, and B. G. Nordestgaard Factor V Leiden Homozygosity, Dyspnea, and Reduced Pulmonary Function Arch Intern Med, September 26, 2005; 165(17): 2032 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Connor Factor V Leiden and Its Effect on Children With Cardiac Pathology Journal of Pediatric Oncology Nursing, May 1, 2005; 22(3): 176 - 181. [Abstract] [PDF]
|
|
|
|
|
|
A. Tybjaerg-Hansen, H. K. Jensen, M. Benn, R. Steffensen, G. Jensen, and B. G. Nordestgaard Phenotype of Heterozygotes for Low-Density Lipoprotein Receptor Mutations Identified in Different Background Populations Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 211 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Vandenbroucke and F. R. Rosendaal Factor V Leiden and Venous Thromboembolism Ann Intern Med, September 21, 2004; 141(6): 484 - 484. [Full Text] [PDF]
|
|
|
|
|
|
P. T. Murphy Factor V Leiden and Venous Thromboembolism Ann Intern Med, September 21, 2004; 141(6): 483 - 484. [Full Text] [PDF]
|
|
|
|
 |
|
 Factor V Leiden and the risk for venous thromboembolism in the adult Danish population Obstet. Gynecol., June 1, 2004; 103(6): 1338 - 1339. [Full Text] [PDF]
|
|
|
|
 |
|
 Factor V Leiden and Risk for Venous Thromboembolism Journal Watch Dermatology, April 28, 2004; 2004(428): 11 - 11. [Full Text]
|
|
|
|
 |
|
 VTE Risk Linked with Factor V Leiden Journal Watch Cardiology, April 23, 2004; 2004(423): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Factor V Leiden and Risk for Venous Thromboembolism Journal Watch (General), March 19, 2004; 2004(319): 5 - 5. [Full Text]
|
|
Read all Rapid Responses
Article
